BCTX — Briacell Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Briacell Reports Outperforming Metastatic Breast Cancer Patients And Standard-Beating Survival Data
Brief: BriaCell Provides Phase 3 Clinical Engagement Update In Metastatic Breast Cancer Pivotal Study
Brief: Briacell Therapeutics Announces Closing Of $5 Million Offering
Brief: Briacell Announces FDA-Authorized Expanded Access Policy For Metastatic Breast Cancer Patients
Brief: BriaCell Therapeutics Announces Closing Of $8.5 Million Offering
BriaCell surges as cancer therapy helps extend patients' lives in study
Brief: Briacell Therapeutics Says Evaluating Bria-BRES In Phase 1/2A Study For Breast Cancer
Brief: Briacell Therapeutics Announces Closing Of $5.0 Mln Registered Direct Offering
Brief: BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering
Brief: BriaCell Executes LOI To Advance Clinical Development Of Breast, Prostate Cancer Immunotherapies
Brief: BriaCell Provides Update On Alleged Illegal Trading Of Public Securities
Brief: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
Brief: Briacell Reports Unprecedented Preliminary Survival And Clinical Benefit In Antibody-Drug Conjugate (Adc) Refractory Patient Subset
Brief: Briacell Highlights Outstanding Topline Survival And Clinical Benefit Data In Advanced Metastatic Breast Cancer At The 2023 Sabcs
Brief: BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit
Briacell Therapeutics Corp reports results for the quarter ended in July - Earnings Summary
Brief: Briacell Partners With New York Cancer & Blood Specialists For Pivotal Phase 3 Study Of Bria-IMT In Advanced Breast Cancer
Brief: Briacell Initiates Pivotal Phase 3 Study Of Bria-Imt™ In Advanced Metastatic Breast Cancer
Brief: Briacell Reports Patient Survival And Clinical Benefit In Advanced Metastatic Breast Cancer